ClinicaliQ Trial Snapshot
- A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors — Recruiting • Phase I • Oncology • NCT06619587.
- What is being tested: GDC-7035, a novel investigational agent, is undergoing first-in-human evaluation for safety, pharmacokinetics, and anti-cancer activity both as monotherapy and in combination with established anti-cancer treatments in a Phase I/II dose-escalation and expansion design.
- Patient eligibility overview: Participants enrolled have advanced or metastatic solid tumors; the study uses a dose-escalation approach to identify tolerability limits before expanding to specific patient cohorts, typical of early-phase oncology trials requiring careful patient selection.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
Eligibility Snapshot
- : * Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation * Agreement to adhere to the contraception requirements described in the protocol for participants of childbearing potential and participants who produce sperm
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.